Search

CET and skills guides

Study and gain CET points through OT’s online CET exams, and access archived CET, CPD articles and skills guides in our education library

Find out more

Science and vision

News and features about the latest scientific developments and advances in optometry, ophthalmology and eye medicine

Find out more

Industry

News and features about the latest developments in optics with a focus on industry

Find out more

Professional support

News and features about the latest developments relating to professional support from across optics. This includes updates from optical organisations such as the AOP and the GOC

Find out more

In practice

News and in-depth features about business management and career development in optics

Find out more

Jobs

Explore the latest UK and global jobs in the optical sector for optometrists, dispensing opticians and more

Find out more

Scientists investigate use of molecular scaffolding to treat eye disease

The molecule protrudin could be used to help heal and regrow damaged nerve cells in the eye, resulting from conditions such as glaucoma

Researchers
New research from the University of Cambridge and the University of Melbourne will investigate the role of molecular scaffolding in helping to heal and grow damaged nerve cells within the eye.

The study, which is funded by Fight for Sight, could lead to new treatments for glaucoma and other conditions.

Scientists also hope that the approach could lead to successful eye transplants by helping a transplanted eye to connect to the eye by growing axons through the optic nerve.

They describe the scaffolding molecule, protrudin, as the “strongest promoter of optic nerve regeneration we have yet encountered.”

Professor Keith Martin, from the University of Cambridge, highlighted that around 10–15% of glaucoma patients go blind in one eye during their lifetime.

“Our work aims to develop new strategies to repair the optic nerve and, ultimately, to restore vision in people who are blind due to optic nerve diseases like glaucoma,” he said.

Image credit: Fight for Sight

Advertisement